ABBOTT LABORATORIES

ABT · XNYS

CIK 1800fmd_1KBDE9BRYH6S97VZZ2P9N27SS4Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2007 to Sep 30, 2026, 76 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	20,853	27,390	30,578	31,904	34,608	43,075	43,653	40,109	41,950	44,328
Cost of revenue	9,094	12,409	12,706	13,231	15,003	18,537	19,142	17,975	18,706	19,319
Gross profit	11,759	14,981	17,872	18,673	19,605	24,538	24,511	22,134	23,244	25,009
Research and development	1,447	2,260	2,300	2,440	2,420	2,742	2,888	2,741	2,844	2,942
Selling, general and administrative	6,736	9,182	9,744	9,765	9,696	11,324	11,248	10,949	11,697	12,332
Operating income	3,026	1,564	3,650	4,532	5,357	8,425	8,362	6,478	6,825	8,053
Interest expense	431	904	826	670	546	533	558	637	559	493
Interest and investment income	99	124	105	94	46	43	183	385	344	308
Other non-operating income (expense)	(786)	1,413	139	191	103	277	321	479	376	548
Income before taxes	1,413	2,231	2,873	4,077	4,968	8,211	8,306	6,664	7,013	8,466
Income tax expense	350	1,878	539	390	497	1,140	1,373	941	(6,389)	1,942
Net income from continuing operations	1,063	353	2,334	3,687	4,471	7,071	6,933	5,723	13,402	6,524
Net income	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402	6,524
Net income to common shareholders	1,393	468	2,353	3,666	4,473	7,042	6,905	5,700	13,400	6,500